Get started
BIOMARIN PHARMABIOMARIN PHARMABIOMARIN PHARMA

BIOMARIN PHARMA

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

BM8 chart


Full chart

BM8 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪9.57 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
24.996
Basic EPS (TTM)
2.433 CHF
Net income (FY)
‪387.67 M‬ CHF
Revenue (FY)
‪2.58 B‬ CHF
Shares float
‪189.17 M‬
Beta (1Y)
0.53

Employees


Employees (FY)
‪3.04 K‬
Change (1Y)
−361 −10.61%
Revenue / Employee (1Y)
‪848.21 K‬ CHF
Net income / Employee (1Y)
‪127.52 K‬ CHF

About BioMarin Pharmaceutical Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Alexander Hardy
Website
biomarin.com
Headquarters
San Rafael
Founded
1997
FIGI
BBG00L7CYBG0
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BM8 news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BM8 highest yielding bonds


BMRN5187965
BioMarin Pharmaceutical Inc. 1.25% 15-MAY-2027
Yield to maturity
4.97%
Maturity date
May 15, 2027

See all BM8 bonds 

Sparks


Curated watchlists where BM8 is featured.

See all sparks 


Check out other big names from the same industry as BM8.

Frequently Asked Questions


The current price of BM8 is 48.753 CHF — it has decreased by −13.21% in the past 24 hours. Watch BIOMARIN PHARMA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange BIOMARIN PHARMA stocks are traded under the ticker BM8.
BM8 stock has fallen by −13.21% compared to the previous week, the month change is a −13.21% fall, over the last year BIOMARIN PHARMA has showed a −39.74% decrease.
We've gathered analysts' opinions on BIOMARIN PHARMA future price: according to them, BM8 price has a max estimate of 103.95 CHF and a min estimate of 53.62 CHF. Watch BM8 chart and read a more detailed BIOMARIN PHARMA stock forecast: see what analysts think of BIOMARIN PHARMA and suggest that you do with its stocks.
BM8 reached its all-time high on Jan 5, 2023 with the price of 100.265 CHF, and its all-time low was 56.175 CHF and was reached on Jan 28, 2025. View more price dynamics on BM8 chart.
See other stocks reaching their highest and lowest prices.
BM8 stock is 15.22% volatile and has beta coefficient of 0.53. Track BIOMARIN PHARMA stock price on the chart and check out the list of the most volatile stocks — is BIOMARIN PHARMA there?
Today BIOMARIN PHARMA has the market capitalization of ‪9.41 B‬, it has increased by 1.46% over the last week.
Yes, you can track BIOMARIN PHARMA financials in yearly and quarterly reports right on TradingView.
BIOMARIN PHARMA is going to release the next earnings report on Aug 5, 2025. Keep track of upcoming events with our Earnings Calendar.
BM8 earnings for the last quarter are 0.84 CHF per share, whereas the estimation was 0.60 CHF resulting in a 39.21% surprise. The estimated earnings for the next quarter are 0.70 CHF per share. See more details about BIOMARIN PHARMA earnings.
BIOMARIN PHARMA revenue for the last quarter amounts to ‪659.64 M‬ CHF, despite the estimated figure of ‪653.89 M‬ CHF. In the next quarter, revenue is expected to reach ‪634.91 M‬ CHF.
BM8 net income for the last quarter is ‪164.38 M‬ CHF, while the quarter before that showed ‪113.47 M‬ CHF of net income which accounts for 44.86% change. Track more BIOMARIN PHARMA financial stats to get the full picture.
No, BM8 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 10, 2025, the company has ‪3.04 K‬ employees. See our rating of the largest employees — is BIOMARIN PHARMA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOMARIN PHARMA EBITDA is ‪635.33 M‬ CHF, and current EBITDA margin is 22.06%. See more stats in BIOMARIN PHARMA financial statements.
Like other stocks, BM8 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOMARIN PHARMA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOMARIN PHARMA technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOMARIN PHARMA stock shows the sell signal. See more of BIOMARIN PHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.